Skip to main content
رجوع
OGN logo

Organon & Co.

جودة البيانات: 100%
ذروة بيع
OGN
NYSE Healthcare Drug Manufacturers - General
KWD 6.11
▲ KWD 0.02 (0.33%)
القيمة السوقية: 1.59B
نطاق اليوم
KWD 5.94 KWD 6.23
نطاق 52 أسبوعًا
KWD 5.94 KWD 15.85
حجم التداول
3,942,656
متوسط 50 يوم / 200 يوم
KWD 7.72 / KWD 8.64
الإغلاق السابق
KWD 6.09

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Healthcare (627 نظير)

المقياس السهم وسيط القطاع
P/E 8.5 0.4
P/B 2.1 2.9
ROE % 30.6 3.7
Net Margin % 3.0 3.9
Rev Growth 5Y % -0.4 10.0
D/E 11.7 0.2

السعر المستهدف للمحللين

Hold
KWD 6.500 +6.4%
Low: KWD 5.000 High: KWD 8.000
مكرر الربحية المستقبلي
1.8
ربحية السهم المستقبلية
KWD 3.467
نمو ربحية السهم (تقدير)
+0.0%
الإيرادات المقدّرة
6.2 B

تقديرات الأرباح

الفترة تقدير ربحية السهم تقدير الإيرادات المحللون
FY2030 KWD 3.900
KWD 3.793 – KWD 3.977
6.5 B 1
FY2029 KWD 3.800
KWD 3.696 – KWD 3.875
6.5 B 1
FY2028 KWD 3.955
KWD 3.847 – KWD 4.033
6.3 B 1

النقاط الرئيسية

Revenue declined -0.35% annually over 5 years
Earnings declined -78.36% over the past year
ROE of 30.56% indicates high profitability
Debt/Equity of 11.70 — high leverage
Generating 538.00M in free cash flow
P/E of 8.51 — trading at a low valuation

النمو

Revenue Growth (5Y)
-0.35%
Revenue (1Y)-2.92%
Earnings (1Y)-78.36%
FCF Growth (3Y)0.00%

الجودة

Return on Equity
30.56%
ROIC10.09%
Net Margin3.01%
Op. Margin20.67%

الأمان

Debt / Equity
11.70
Current Ratio1.82
Interest Coverage2.55

التقييم

P/E Ratio
8.51
P/B Ratio2.12
EV/EBITDA7.64
Dividend Yield0.05%

All Fundamental Metrics

Growth
Revenue Growth (1Y) -2.92% Revenue Growth (3Y) -0.38%
Earnings Growth (1Y) -78.36% Earnings Growth (3Y) -57.25%
Revenue Growth (5Y) -0.35% Earnings Growth (5Y) -39.00%
Profitability
Revenue (TTM) 6.22B Net Income (TTM) 187.00M
ROE 30.56% ROA 1.45%
Gross Margin 54.09% Operating Margin 20.67%
Net Margin 3.01% Free Cash Flow (TTM) 538.00M
ROIC 10.09% FCF Growth (3Y) 0.00%
Safety
Debt / Equity 11.70 Current Ratio 1.82
Interest Coverage 2.55 Dividend Yield 0.05%
Valuation
P/E Ratio 8.51 P/B Ratio 2.12
P/S Ratio 0.26 PEG Ratio -0.13
EV/EBITDA 7.64 Dividend Yield 0.05%
Market Cap 1.59B Enterprise Value 9.82B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 6.22B 6.40B 6.26B 6.17B 6.30B
Net Income 187.00M 864.00M 1.02B 917.00M 1.35B
EPS (Diluted) 0.72 3.33 3.99 3.59 5.33
Gross Profit 3.36B 3.72B 3.75B 3.88B 3.92B
Operating Income 1.29B 1.49B 1.33B 1.71B 1.92B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 12.87B 13.10B 12.06B 10.96B 10.68B
Total Liabilities 12.12B 12.63B 12.13B 11.85B 12.19B
Shareholders' Equity 752.00M 472.00M -70.00M -892.00M -1.51B
Total Debt 8.80B 9.04B 8.93B 9.11B 9.36B
Cash & Equivalents 574.00M 675.00M 693.00M 706.00M 737.00M
Current Assets 4.35B 4.35B 4.51B 3.93B 3.76B
Current Liabilities 2.39B 2.72B 2.92B 2.51B 2.60B

درجات الاستراتيجيات

This stock passed the criteria for 1 strategy

Score = fit strength (0–100)
Rank = position among all matches
#165 of 658
49

النشاط الأخير

دخل Contrarian Investing (David Dreman)
Mar 24, 2026